

# Jong Gwang Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6039836/publications.pdf>

Version: 2024-02-01

136  
papers

3,924  
citations

257101

24  
h-index

133063

59  
g-index

136  
all docs

136  
docs citations

136  
times ranked

6056  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	6.3	1,749
2	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	2.7	155
3	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22â€“05): a single-arm, phase 1bâ€“2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1066-1076.	5.1	130
4	Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 62-66.	3.2	111
5	Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 129-134.	1.1	107
6	Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. <i>European Journal of Haematology</i> , 2004, 73, 56-61.	1.1	74
7	CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1005-1014.	1.2	64
8	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	2.7	61
9	Quercetin-induced apoptosis prevents EBV infection. <i>Oncotarget</i> , 2015, 6, 12603-12624.	0.8	61
10	CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 35-39.	1.1	60
11	Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2005, 46, 885-891.	0.6	58
12	Optimal treatment strategies for clinically suspicious lateral pelvic lymph node metastasis in rectal cancer. <i>Oncotarget</i> , 2017, 8, 100724-100733.	0.8	55
13	Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. <i>International Journal of Hematology</i> , 2009, 90, 383-387.	0.7	54
14	A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. <i>Anticancer Research</i> , 2013, 33, 3233-9.	0.5	49
15	Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 293.	0.8	48
16	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	2.7	45
17	Intratatumoural PD-L1 expression is associated with worse survival of patients with Epsteinâ€“Barr virus-associated gastric cancer. <i>British Journal of Cancer</i> , 2017, 117, 1753-1760.	2.9	40
18	TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 355-360.	1.1	39

#	ARTICLE	IF	CITATIONS
19	Phase II Study of Docetaxel and Capecitabine in Patients with Metastatic or Recurrent Gastric Cancer. <i>Oncology</i> , 2005, 68, 190-195.	0.9	38
20	Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer. <i>Oncology</i> , 2015, 89, 351-359.	0.9	37
21	Association between Phosphorylated AMP-Activated Protein Kinase and MAPK3/1 Expression and Prognosis for Patients with Gastric Cancer. <i>Oncology</i> , 2013, 85, 78-85.	0.9	36
22	High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. <i>Oncotarget</i> , 2017, 8, 14988-14994.	0.8	34
23	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. <i>European Journal of Cancer</i> , 2020, 130, 51-62.	1.3	34
24	Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 6973-6979.	0.5	30
25	Molecular targeted therapy for advanced gastric cancer. <i>Korean Journal of Internal Medicine</i> , 2013, 28, 149.	0.7	26
26	Genetic polymorphism of miR-196a as a prognostic biomarker for early breast cancer. <i>Anticancer Research</i> , 2014, 34, 2943-9.	0.5	24
27	Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 953-960.	1.1	22
28	Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. <i>Anticancer Research</i> , 2017, 37, 1459-1466.	0.5	22
29	Harvesting peripheral blood stem cells from healthy donors on 4th day of cytokine mobilization. <i>Journal of Clinical Apheresis</i> , 2003, 18, 186-189.	0.7	21
30	Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 246-253.	1.3	21
31	RIPK1 and CASP7 polymorphism as prognostic markers for survival in patients with colorectal cancer after complete resection. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 705-713.	1.2	20
32	Genetic Variations in STK11, PRKAA1, and TSC1 Associated with Prognosis for Patients with Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 634-639.	0.7	20
33	Association between GWAS-Identified Genetic Variations and Disease Prognosis for Patients with Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0119649.	1.1	20
34	Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. <i>Anticancer Research</i> , 2015, 35, 2775-82.	0.5	20
35	Functional polymorphism in the MicroRNA-367 binding site as a prognostic factor for colonic cancer. <i>Anticancer Research</i> , 2013, 33, 513-9.	0.5	18
36	Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 863-869.	1.1	17

#	ARTICLE	IF	CITATIONS
37	DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma. <i>Archives of Pharmacal Research</i> , 2017, 40, 894-905.	2.7	17
38	Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. <i>Medical Oncology</i> , 2018, 35, 145.	1.2	17
39	High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients with locally advanced rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 105-115.	1.2	17
40	Clinical significance of nuclear factor $\kappa$ B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 785.	0.7	17
41	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. <i>Blood Research</i> , 2014, 49, 15.	0.5	16
42	Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 571-577.	1.1	15
43	Taxanes in the Treatment of Advanced Gastric Cancer. <i>Molecules</i> , 2016, 21, 651.	1.7	14
44	Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1775-1780.	1.2	14
45	Exon 9 Mutation of <i>PIK3CA</i> Associated With Poor Survival in Patients With Epstein-Barr Virus-associated Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 2145-2154.	0.5	14
46	Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 735-741.	1.1	13
47	Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 35-41.	1.2	13
48	Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. <i>Radiation Oncology Journal</i> , 2017, 35, 208-216.	0.7	13
49	Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 223-239.	1.3	13
50	Clinical Significance of Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway in Korean Patients with Colorectal Cancer. <i>Oncology</i> , 2010, 79, 278-282.	0.9	12
51	HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 413-423.	1.4	12
52	Quercetin Synergistically Inhibit EBV-Associated Gastric Carcinoma with <i>Ganoderma lucidum</i> Extracts. <i>Molecules</i> , 2019, 24, 3834.	1.7	12
53	Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 4003-4010.	0.5	11
54	Absolute lymphocyte count at day +21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone. <i>Leukemia and Lymphoma</i> , 2012, 53, 1757-1763.	0.6	10

#	ARTICLE	IF	CITATIONS
55	Adenosine Induces EBV Lytic Reactivation through ADORA1 in EBV-Associated Gastric Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1286.	1.8	10
56	Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 1671-1675.	1.2	9
57	PPP1R13L variant associated with prognosis for patients with rectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 465-473.	1.2	9
58	Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 894-899.	0.7	9
59	Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer. <i>In Vivo</i> , 2019, 33, 649-657.	0.6	9
60	Short-term outcomes after laparoscopic cytoreductive surgery in patients with limited peritoneal metastases from colorectal cancer. <i>Surgery</i> , 2019, 165, 775-781.	1.0	9
61	Prognostic Impact of the Neoadjuvant Rectal Score as Compared With the Tumor Regression Grade and Yield Pathologic TNM Stage in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>In Vivo</i> , 2020, 34, 1993-1999.	0.6	9
62	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	2.7	9
63	Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis Type I : Unusual Presentation of Intraabdominal or Intrathoracic Mass. <i>Korean Journal of Internal Medicine</i> , 2005, 20, 100.	0.7	9
64	A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy. <i>Cancer Research and Treatment</i> , 2014, 46, 19-26.	1.3	9
65	Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. <i>Anticancer Research</i> , 2015, 35, 3531-6.	0.5	9
66	No Association of the NFKB1 Insertion/Deletion Promoter Polymorphism with Survival in Patients with Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2009, 39, 497-501.	0.6	8
67	AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer. <i>Oncology</i> , 2017, 92, 153-160.	0.9	8
68	Prognostic Significance of Clinicopathological and Molecular Features After Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients. <i>In Vivo</i> , 2019, 33, 1959-1965.	0.6	8
69	Predictive Value of Circulating miRNAs in Lymph Node Metastasis for Colon Cancer. <i>Genes</i> , 2021, 12, 176.	1.0	8
70	Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer. <i>Anticancer Research</i> , 2016, 36, 3353-61.	0.5	8
71	Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Caseâ€“Control Study from a Single Center. <i>Annals of Surgical Oncology</i> , 2016, 23, 2266-2273.	0.7	7
72	Elevated Neutrophilâ€“toâ€“Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy. <i>Anticancer Research</i> , 2018, 38, 3151-3156.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor $\alpha$ 2 gene polymorphisms in patients with gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, e40-5.	0.7	6
74	The Predictive Value of Epstein-Barr Virus-Positivity in Patients Undergoing Gastrectomy Followed by Adjuvant Chemotherapy. <i>Chonnam Medical Journal</i> , 2018, 54, 173.	0.5	6
75	ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy. <i>Anticancer Research</i> , 2019, 39, 2845-2853.	0.5	6
76	Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 501-508.	1.1	6
77	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110428.	1.4	6
78	Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 187-193.	1.1	5
79	Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. <i>Chonnam Medical Journal</i> , 2017, 53, 140.	0.5	5
80	Recent advances in chemotherapy for advanced gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2010, 2, 287.	0.8	5
81	Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1263-1267.	1.1	4
82	Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer. <i>International Journal of Colorectal Disease</i> , 2021, 36, 1279-1286.	1.0	4
83	Clinical Significance of Autoantibody Expression in Allogeneic Stem Cell Recipients.. <i>Blood</i> , 2008, 112, 2205-2205.	0.6	4
84	Clinical Impact of Prognostic Nutrition Index for Advanced Gastric Cancer Patients with Peritoneal Metastases Treated Nivolumab Monotherapy. <i>Chonnam Medical Journal</i> , 2022, 58, 24.	0.5	4
85	Clinical Impact of Postoperative Vitamin D Deficiency on the Recurrence of Colon Cancer After Curative Surgical Resection. <i>Anticancer Research</i> , 2021, 41, 3683-3688.	0.5	3
86	IL-10 Promoter Gene Polymorphism Associated with the Occurrence of Chronic GVHD and Its Clinical Course during Systemic Immunosuppressive Treatment for Chronic GVHD after Allogeneic Peripheral Blood Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 422-422.	0.6	3
87	AQP1 expression and survival in patients with colon cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e14586-e14586.	0.8	3
88	Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011-2014: A nationwide study based on the database of quality assessment and the health insurance.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3605-3605.	0.8	3
89	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). <i>Gastric Cancer</i> , 2022, 25, 609-618.	2.7	3
90	Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma. <i>Journal of Korean Medical Science</i> , 2004, 19, 820.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Clinical Significance of <i>MET</i> Gene Copy Number in Patients with Curatively Resected Gastric Cancer. Chonnam Medical Journal, 2015, 51, 81.	0.5	2
92	Pharmacokinetic and bioequivalence study between two formulations of S-1 in Korean gastric cancer patients. Drug Design, Development and Therapy, 2019, Volume 13, 3127-3136.	2.0	2
93	Transplantation with Higher Dose of Natural Killer Cells Associated with Better Outcomes in Terms of Non-Relapse Mortality and Infectious Events after Allogeneic Peripheral Blood Stem Cell Transplantation from HLA-Matched Sibling Donors.. Blood, 2004, 104, 733-733.	0.6	2
94	Multicenter randomized phase II study of weekly docetaxel alone versus weekly docetaxel plus oxaliplatin as a second-line chemotherapy in patients with advanced gastric cancer: Preliminary response and safety results.. Journal of Clinical Oncology, 2012, 30, e14570-e14570.	0.8	2
95	Genetic variations in miRNA binding site of <i>TPST1</i> and <i>ZG16B</i> associated with prognosis for patients with colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 3553-3553.	0.8	2
96	Phosphorylated AMP-activated protein kinase and MAPK3/1 expression associated with prognosis for patients with gastric cancer.. Journal of Clinical Oncology, 2013, 31, 36-36.	0.8	2
97	Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study. , 2022, 39, 141-149.		2
98	Current Trends in Studies of Epstein-Barr Virus (EBV) Associated Gastric Carcinoma. Journal of Bacteriology and Virology, 2015, 45, 262.	0.0	1
99	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. Journal of Clinical Oncology, 2021, 39, 4056-4056.	0.8	1
100	Cisplatin Resistance in Epstein-Barr-Virus-Associated Gastric Carcinoma Acquired through ATM Methylation. Cancers, 2021, 13, 4252.	1.7	1
101	Comparing Standard IPI with Revised-IPI in Patients with Diffuse Large B-Cell Lymphoma: Which Has a More Differential Potential for Predicting the Outcomes after R-CHOP Chemotherapy.. Blood, 2008, 112, 2003-2003.	0.6	1
102	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 492-492.	0.8	1
103	Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. Korean Journal of Internal Medicine, 2020, 35, 185-193.	0.7	1
104	Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer. Cancer Diagnosis & Prognosis, 2022, 2, 78-83.	0.3	1
105	Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC).. Journal of Clinical Oncology, 2022, 40, TPS3639-TPS3639.	0.8	1
106	Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemotherapy and Pharmacology, 2015, 76, 29-34.	1.1	0
107	Impact of Anatomic Extent of Nodal Metastasis on Adjuvant Chemotherapy Outcomes in Stage III Colon Cancer. Diseases of the Colon and Rectum, 2020, 63, 1455-1465.	0.7	0
108	Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial.. Journal of Clinical Oncology, 2021, 39, 3598-3598.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Bcl-2 Mediated Apoptosis Interacts with p53-Dependent Pathway in Progression of Peripheral T-Cell Lymphoma.. Blood, 2004, 104, 4548-4548.	0.6	0
110	Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 5337-5337.	0.6	0
111	Multidrug Resistance-1 Gene Polymorphism Associated with the Outcomes after Allogeneic HLA-Identical Stem Cell Transplantation.. Blood, 2005, 106, 1757-1757.	0.6	0
112	Time to First Acute Exacerbation Can Stratify the Patients According to Their Prognosis during Clinical Course of Chronic GVHD: Evaluation of New End-Point for Chronic GVHD.. Blood, 2005, 106, 5335-5335.	0.6	0
113	Rapid Helper T-Cell Recovery at 3 Months Correlates to Successful Transplant Outcomes after Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 5201-5201.	0.6	0
114	Survival Benefit of Asymptomatic Cytomegalovirus Reactivation and Early Lymphocyte Recovery after HLA-Identical Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2005, 106, 5336-5336.	0.6	0
115	Risk Factors for Predicting CMV Infection in Allogeneic-PBSCT Setting: MNC Dose, Campath Use, and Acute GVHD Grade .. Blood, 2006, 108, 5298-5298.	0.6	0
116	Treatment Outcomes for Imatinib Mesylate and Allogeneic Stem Cell Transplantation in Patients with CML Based on RQ-PCR, and the Efficacy of Dose Escalation of Imatinib Mesylate in Patients with Cytogenetic or Hematologic Resistance.. Blood, 2006, 108, 4762-4762.	0.6	0
117	Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.. Blood, 2006, 108, 4670-4670.	0.6	0
118	Retrospective Analysis of Post-Remission Modalities in AML Patients with Normal Karyotype.. Blood, 2007, 110, 4258-4258.	0.6	0
119	The Mobilization Effects of G-CSF, GM-CSF and Darbepoetin- $\alpha$ for Allogeneic Peripheral Blood Stem Cell Transplantation.. Blood, 2007, 110, 4932-4932.	0.6	0
120	Early Onset of Acute Graft-Versus-Host Disease Indicating a Worse Prognosis in Terms of Chronic Graft-Versus-Host Disease and Survival Compared to Late Onset.. Blood, 2007, 110, 4979-4979.	0.6	0
121	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. Blood, 2009, 114, 5017-5017.	0.6	0
122	<i>PPP1R13L</i> variant as a prognostic factor in patients with rectal cancer.. Journal of Clinical Oncology, 2012, 30, e14074-e14074.	0.8	0
123	Prognostic impact of miR-146 polymorphism in patients with resected colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 3554-3554.	0.8	0
124	The outcomes of allogeneic stem cell transplantation in AML patients with monosomal karyotypes.. Journal of Clinical Oncology, 2012, 30, 6538-6538.	0.8	0
125	Clinical significance of nuclear kappa B and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2012, 30, e18533-e18533.	0.8	0
126	Impact of ATG on new HLA groups for unrelated donor allogeneic stem cell transplantation.. Journal of Clinical Oncology, 2012, 30, 6536-6536.	0.8	0



#	ARTICLE	IF	CITATIONS
127	AQP5 variant associated with prognosis in patients with early breast cancer.. Journal of Clinical Oncology, 2013, 31, e11505-e11505.	0.8	0
128	Functional polymorphism in the microRNA-367 binding site as a prognostic factor for colonic cancer.. Journal of Clinical Oncology, 2013, 31, e14549-e14549.	0.8	0
129	Association of expression of aquaporin 5 (AQP5) with prognosis in hormone-responsive early breast cancer patients.. Journal of Clinical Oncology, 2013, 31, e11594-e11594.	0.8	0
130	Impact of antithymocyte globulin on new HLA groups for unrelated donor allogeneic stem cell transplantation.. Journal of Clinical Oncology, 2013, 31, e18017-e18017.	0.8	0
131	Genetic polymorphism in the miR-196a as a prognostic biomarker for early breast cancer.. Journal of Clinical Oncology, 2014, 32, e22058-e22058.	0.8	0
132	Genetic variant in the microRNA binding site of DOK3 (rs2279398G>A) and susceptibility to colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 1537-1537.	0.8	0
133	Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e22230-e22230.	0.8	0
134	Effect of MiR-137 and MiR-496 on Del-1 and triple negative breast cancer progression.. Journal of Clinical Oncology, 2017, 35, e23058-e23058.	0.8	0
135	Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma.. Journal of Clinical Oncology, 2020, 38, e14532-e14532.	0.8	0
136	Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	0